

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

**Diagnostics Advisory Committee (DAC)**

**Minutes of the Meeting on Wednesday 22 May 2019**

Level 1A City Tower, Piccadilly Plaza, Manchester M1 4BD

**PRESENT:**

**Standing Committee members:**

Dr Mark Kroese (Chair)  
Ms Liz Adair  
Mr John Bagshaw  
Professor Enitan Carrol  
Dr Owen Driskell  
Dr Simon Fleming  
Dr Jim Gray  
Professor Steve Halligan  
Mr John Hitchman  
Professor Christopher Hyde  
Dr Sandeep Kapur  
Mr Patrick McGinley  
Dr Michael Messenger  
Mrs Alexandria Moseley  
Professor Matt Stevenson  
Professor Anthony Wierzbicki

**Standing Committee apologies:**

Dr Shelley Rahman Haley  
Dr Neil Hawkins  
Dr Simon Richards  
Professor Mark Sculpher

**NICE staff in attendance:**

Sarah Byron, Associate Director, DAP  
Rebecca Albrow, Senior Technical Adviser, DAP  
Frances Nixon (Technical lead) Technical Analyst, DAP  
Christopher Pomfrett, Technical Adviser, MTEP  
Donna Barnes, Project Manager, DAP  
Alex Sexton, Administrator, DAP

**Observing:**

Sarah Bromley, Medical Editor, NICE  
Ana Duarte, Research Fellow, University of York  
Ann Greenwood, Senior Medical Editor, NICE  
Gareth Murphy, Business Analyst, NICE  
Katie Wyart, Medical Technology Implementation Manager, NICE

**1. Introduction to the meeting**

The Chair welcomed Committee members, observers and members of the public.

The Chair noted that this was Dr Simon Fleming's last meeting after serving on the committee for over nine years and he thanked Dr Fleming for his considerable work and contributions in this time.

The Chair further noted that Dr Nick Summerton was no longer able to continue as a committee member and had stepped down with immediate effect. He recorded the committee's thanks to Dr Summerton for his work over the past year.

Apologies were noted.

**2. Code of conduct for members of the public attending the meeting**

The Chair explained the code of conduct to the members of the public attending this meeting.

**3. Any other business**

No other business was offered.

**4. Minutes from the last Committee meeting**

The Committee agreed the minutes from the 16 April 2019 Committee meeting.

**5. Equality and Diversity**

The Chair reminded the Committee to raise any potential equality issues related to the topic under discussion.

**Assessment of point-of-care creatinine tests to assess kidney function before administering intravenous contrast for computed tomography (CT) imaging**

**External Assessment Group representatives: Centre for Reviews and Dissemination (CRD) and Centre for Health Economics (CHE), University of York**

Mark Corbett, Research Fellow, CRD, University of York,  
Professor Sofia Dias, CRD, University of York,  
Professor Stephen Palmer, CHE, University of York

**Specialist Committee members:**

Dr Jane Belfield, Clinical Director, Radiology Department  
Anne Dawnay, Consultant Biochemist  
Dr Mark Devonald, Consultant Nephrologist  
Guy Hill, Lay specialist committee member  
Emily Lam, Lay specialist committee member  
Dr Andrew Lewington, Consultant Renal Physician  
Professor Beverly Snaith, Clinical Professor of Radiology

**Specialist Committee members apologies:**

Annette Thomas, Consultant Clinical Scientist

**PART 1 AND PART 2 (open and closed parts of the meeting).**

**Part 1 – Open session**

The Chair welcomed representatives from Fujifilm UK Ltd and Abbott Diagnostics.

There were 2 public attendees.

The Chair asked Committee members to declare any updates to declared interests.

The following standing committee members had declared interests:

Liz Adair had declared an indirect interest as Abbott Diagnostics, Radiometer and Siemens Healthineers supply products and equipment to Viapath Services LLP where she is employed as the Quality Director. It was agreed that this interest did not preclude her from taking part in the meeting.

Dr Simon Fleming had declared an indirect non-financial interest as Abbott Diagnostics provides equipment and reagents to the laboratory he works in, but not point of care tests. It was agreed that this interest did not preclude him from taking part in the meeting.

Dr Sandeep Kapur had declared interests as he is a BNF Joint Formulary Committee Member since August 2018; a GMC PLAB examiner since July 2018, and a CQC GP advisor since July 2018, and is a physician at the Mayo Clinic London in partnership with Oxford University Clinic. It was agreed that these interests did not preclude him from taking part in the meeting.

Dr Michael Messenger had declared non-financial professional and personal interests as he is co-investigator on the "Bias Estimation Point of Care Creatinine" (BEPoCC ISRCTN 18805212) and "Streamlining cross-sectional imaging pathways" (SCIPs ISRCTN 67296844) studies. It was agreed that these interests did not preclude him from taking part in the meeting.

Dr Simon Richards had declared a direct financial interest as he is employed as VP of Regulatory Affairs by Abbott Rapid Diagnostics. It was agreed that this interest precluded him from participating in the meeting and he did not attend.

Prof Anthony Wierzbicki had declared he is a clinical trial investigator for Akcea, and Regeneron, and had been for Amgen; he had been a clinical registry investigator for Chiesi, and is Chair of the NICE kidney guidelines update. It was agreed that these interests did not preclude him from taking part in the meeting.

The following specialist committee members had declared interests:

Dr Mark Devonald had declared indirect interests as he had received unconditional educational grants from MSD, Alexion and Stanningley Pharma to support the Nottingham Acute Kidney Injury Course (for which he is the course director) but had not received any personal honoraria. He is co-inventor in patent application 'Biomarkers related to kidney function and methods involving their use' International publication number: WO 2016/110701 A1 (international publication date 14 July 2016). (patent owners: Nottingham University Hospitals NHS Trust and University of Nottingham). It was agreed that these interests did not preclude her from taking part in the meeting.

Dr Andrew Lewington had declared interests as he is Associate Clinical Director NIHR Leeds In Vitro Diagnostic Cooperative and in this role engages with industry to help the development and delivery of new IVDs for the NHS. He is also Co Chair of UK Kidney Research Consortium Acute Kidney Injury Clinical Study Group and engages with industry to discuss potential AKI studies that could be developed with potential funding from industry or through partnering on grant applications. He had also declared that he attended the Acute Dialysis Quality Initiative (ADQI) – Quality Improvement Conference San Diego November 2018 and received expenses to cover two nights accommodation. He attended the AKI conference in Coventry in March 2019 to give a lecture on AKI diagnostics and his train fare was paid for. He attended the NIHR Leeds Sepsis and AKI Worksop to Identify Unmet Clinical Need in May 2019 to lecture on AKI and Sepsis and AKI Diagnosis and Treatment. It was agreed that these interests did not preclude him from taking part in the meeting.

Dr Beverley Snaith had declared non-financial interests as she is Chief investigator on research studies investigating the topic under review (and relevant publications) in receipt of grants from NHS England and Y&H AHSN. This includes loan of equipment from 3 device companies for investigation. In the meeting she further declared an interest in that she is the co-author on a paper considered by the EAG as part of the Diagnostics Assessment Report for the topic under consideration. It was agreed that these interests did not preclude her from taking part in the meeting.

Dr Annette Thomas had declared an indirect interest as Weqas provides an EQA programme to monitor the performance of POCT creatinine devices across the UK. Weqas is a not for profit organisation hosted by Cardiff and Vale UHB where she is employed. She also declared a non-financial professional interest as from August 2017 to January 2018 she had been an expert commentator on NICE Medtech innovation briefing – MIB 136, POCT Creatinine use before contrast enhanced imaging. It was agreed that these interests did not preclude her from taking part in the meeting.

The Committee proceeded to discuss the clinical effectiveness and cost effectiveness of point-of-care creatinine tests to assess kidney function before administering intravenous contrast for computed tomography (CT).

The Committee was asked if there were any specific equality issues to consider in relation to this assessment.

The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest” (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and all public attendees left the meeting.

The Chair thanked the manufacturer representatives for their attendance and participation in the meeting.

## **End of Part 1**

## **Part 2 – closed session**

Agreement on the content of the Diagnostic Consultation Document (DCD) was discussed by the committee.

## **End of Part 2**

## **Date, time and venue of next meeting**

Monday 17 June 2019 at the National Institute for Health and Care Excellence, Level 1A, City Tower, Piccadilly Plaza, Manchester M1 4BD.